A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery

Inclusion Criteria: * eGFR ≥30 ml/min/1.73m2 * Scheduled for non-emergent surgery of any of the following types, with use of cardiopulmonary bypass (CPB): coronary artery bypass grafting (CABG), valve surgery, ascending aorta aneurysm surgery * Risk factors for acute kidney injury are present * Participant capable of providing written informed consent * Participant agrees to study restrictions such as not to take part in another interventional study, use contraception and not donate ova or sperm Exclusion Criteria: * Any medical condition that makes the participant unsuitable * Scheduled for emergent surgeries * Scheduled for CABG and/or valve surgery and/or ascending aorta aneurysm surgery combined with additional non-emergent cardiac surgeries * Scheduled to undergo transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR), or off-pump surgeries or left ventricular assist device (LVAD) implantation * Experiences a cardiogenic shock or hemodynamic instability which require inotropes or vasopressors or other mechanical devices such as intraaortic balloon pumping (IABP) within 24 hours prior to surgery * Requires any of the following within one week prior to surgery: defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, other forms of mechanical circulatory support. * Diagnosed with AKI prior to surgery * Requires cardiopulmonary resuscitation prior to surgery * Ongoing sepsis or an untreated diagnosed clinically significant infection * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3.0 times the upper limit of normal (ULN). * Total bilirubin ≥2.0 time ULN * History of solid organ transplantation * History of renal replacement therapy * Severe allergic asthma * Chronic immunosuppressive treatment that may have an impact on kidney function * Ongoing chemotherapy or radiation therapy for malignancy that may have an impact on kidney function * Current enrolment or past recent participation in any other clinical study involving an investigational study treatment * Previously treatment of RMC-035 * Sensitivity to any of the study interventions, or components thereof